SBIR-STTR Award

Tissue Oxygen Scanning for Acute Compartment Syndrome (ACS) Diagnosis
Award last edited on: 2/9/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NIAMS
Total Award Amount
$276,073
Award Phase
1
Solicitation Topic Code
846
Principal Investigator
Shai Ashkenazi

Company Information

Ascan LLC

3230 Cavell Lane
Saint Louis Park, MN 55426
   (734) 657-5952
   N/A
   www.ascan-llc.com
Location: Single
Congr. District: 05
County: Hennepin

Phase I

Contract Number: 2023
Start Date: ----    Completed: 6/1/2023
Phase I year
2023
Phase I Amount
$276,073
Acute compartment syndrome (ACS) is a complication of extremity injury caused by increasingly elevated intracompartmental pressure (ICP) that eventually compromises perfusion, causing ischemia of the muscles within the compartment. If this persists longer than 6-8 hours, permanent ischemic damage to the muscle occurs (myofibrosis and ischemic contracture). ACS demands immediate surgical fasciotomy to restore tissue perfusion, yet early ACS diagnosis is problematic because of the current lack of a reliable diagnostic standard. Surgeons rely on clinical judgment and index of suspicion to diagnose and make treatment decisions. Since delayed fasciotomy is the most important factor contributing to poor outcomes; treatment decisions are biased towards early intervention, often leading to unnecessary fasciotomy procedures. Since clinical findings are subjective, measurement of ICP is commonly used despite lack of consensus regarding a threshold for performing fasciotomy Research is needed to identify new methods to diagnose ACS. ICP is the most common objective test used to diagnose ACS, but ICP does not tell the clinician whether the involved muscles are healthy, ischemic, or necrotic, and has poor diagnostic specificity. Current ICP devices provide only a single-point pressure measurement, although it has been shown that ICP varies throughout the compartment. Furthermore, measurement of pressure via a percutaneous needle is subject to sampling and technical error. These factors contribute to uncertainty about the ICP reading and therefore the diagnosis. Here we propose developing a new method to diagnose ACS by measuring a depth profile of tissue oxygen in the affected muscle. A-Scan LLC (Minneapolis, MN) has developed an optical scanning needle probe that scans pO2 along its length without mechanical movement. In this project we will characterize the device performance and then test it in a swine model that replicates the pathophysiology of ACS. Commercially, the market of ACS diagnosis is derived from the fact that ACS is considered in every case of tibia fracture. Considering an annual incidence of 300,000 tibia fractures in the US, the market is estimated at $90 million. This phase I of the project plan will focus on validating the functionality and performance of the probe in a large animal model. In a future phase II extension we plan to significantly advance the process of commercializing the device. It includes optimizing the device design for clinical application, perform testing and device characterization for complying with FDA regulatory requirements and complete an initial request for information (Q-Submission) to the FDA in order to obtain a specific device classification code and a pathway to marketing clearance.

Public Health Relevance Statement:
NARRATIVE Acute compartment syndrome (ACS) is a high-risk condition following extremity injury that can lead to irreversible damage to muscles. Current methods of ACS diagnosis are imprecise, difficult to perform, and result in unnecessary surgical interventions. Here we propose developing an ACS diagnosis device based on scanning tissue oxygen in the affected muscle.

Project Terms:
Algorithms; bone; Malignant Neoplasms; Cancers; Malignant Tumor; malignancy; neoplasm/cancer; Certification; Classification; Systematics; Compartment syndromes; Complication; Contracture; Diagnosis; Fracture; bone fracture; Future; Health; Hospitalization; Hospital Admission; Incidence; indexing; Ischemia; Joints; Judgment; Marketing; Methods; Movement; body movement; Mus; Mice; Mice Mammals; Murine; Muscle; Muscle Tissue; muscular; Myoglobin; Necrosis; Necrotic; Needles; Optics; optical; Oxygen; O element; O2 element; Perfusion; pressure; Reading; Research; Sampling Errors; statistics; Family suidae; Pigs; Suidae; Swine; porcine; suid; Temperature; Testing; tibia; Tissues; Body Tissues; Tourniquets; Ultrasonography; Echography; Echotomography; Medical Ultrasound; Ultrasonic Imaging; Ultrasonogram; Ultrasound Diagnosis; Ultrasound Medical Imaging; Ultrasound Test; diagnostic ultrasound; sonogram; sonography; sound measurement; ultrasound imaging; ultrasound scanning; Measures; Device Designs; Dissociation; doubt; Uncertainty; injuries; Injury; improved; Procedures; Site; Acute; Clinical; Specified; Specific qualifier value; Phase; Hypoxic; Oxygen Deficiency; Hypoxia; Data Bases; data base; Databases; Measurement; Early Intervention; Dysfunction; Physiopathology; pathophysiology; Functional disorder; Diagnostic; Consensus; Mechanics; mechanic; mechanical; Unnecessary Surgery; Isolated limb perfusion; Limb Perfusion; Hour; Dependence; Scanning; brain tissue; Operative Surgical Procedures; Operative Procedures; Surgical; Surgical Interventions; Surgical Procedure; surgery; Surgeon; Early Diagnosis; early detection; Performance; diagnostic accuracy; Accuracy of Diagnosis; Animal Model; Animal Models and Related Studies; model of animal; Speed; novel; Devices; Reporting; Positioning Attribute; Position; limb injury; extremity injury; extremity trauma; injury to extremity; limb trauma; Code; Coding System; Sampling; performance tests; Property; tissue oxygenation; tissue oxygen saturation; Length; Tissue Viability; Diagnostic Specificity; in vivo; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Process; Hindlimb; Pathway interactions; pathway; designing; design; Outcome; clinical applicability; clinical application; commercialization; tumor; high risk; FDA approved; brain oxygenation; cerebral oxygenation; in vivo testing; in vivo evaluation; injury to tissue; tissue injury; pig model; piglet model; swine model; porcine model; Affect

Phase II

Contract Number: 1R43AR082738-01
Start Date: 5/31/2024    Completed: 00/00/00
Phase II year
----
Phase II Amount
----